(2) α1,3-galactosyltransferase gene-knockout was an essential step towards successful pig organ transplantation in primates

Xenotransplantation

Volumn 14, Issue 2, 2007, Pages 182-183

  Cooper, David K C ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; CD39 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOSUPPRESSIVE AGENT; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADD ON THERAPY; BLOOD CLOTTING DISORDER; CARDIAC GRAFT REJECTION; CONFERENCE PAPER; CONTINUOUS INFUSION; GENETIC ENGINEERING; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT GENE; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; SWINE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 33947387449     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2007.00386_7.x     Document Type: Conference Paper

References (21)

1. Cooper DKC, Koren E, Oriol R. Genetically engineered pigs. Lancet 1993; 342: 682-683.
2. Phelps CJ, Koike C, Vaught TD et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
3. Kolber-Simonds D, Lai L, Watt SR et al. Production of a1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci U S A 2004; 101: 7335-7340.
4. Kuwaki K, Tseng Y-L, Dor FJMF et al. Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31.
5. Tseng Y-L, Kuwaki K, Dor FJMF et al. α1,3-galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching six months. Transplantation 2005; 80: 1493-1500.
6. Yamada K, Yazawa K, Shimizu A et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3- galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11: 32-34.
7. Houser SL, Kuwaki K, Knosalla C et al. Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11: 416-425.
8. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-966.
9. Kuwaki K, Knosalla C, Dor FJMF et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-CD154 monoclonal antibody-based regimen. Am J Transplant 2004; 4: 363-372.
10. Kirk AD, Harlan DM. Reply: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2001; 6: 114.
11. McGregor CG, Teotia SS, Byrne GW et al. Cardiac xenotransplantation: progress toward the clinic. Transplantation 2004; 78: 1569-1575.
12. McGregor CG, Davies WR, Oi K et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
13. Hara H, Ezzelarab M, Rood PPM et al. Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation 2006; 13: 357-365.
14. Ezzelarab E, Hara H, Busch J et al. Antibodies directed to pig nonGal antigens in naïve and sensitized baboons. Xenotransplantation 2006; 13: 400-407.
15. Rood PPM, Hara H, Busch J et al. Incidence and cytotoxicity of antibodies in cynomolgus monkeys directed to nonGal antigens, and their relevance for experimental models. Transpl Int 2006; 19: 158-165.
16. Chen G, Qian H, Starzl T et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11: 1295-1298.
17. Chen D, Weber M, McVey JH et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4: 1958-1963.
18. Dwyer KM, Robson SC, Nandurkar HH et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004: 113: 1440-1446.
19. Mendicino M, Liu M, Ghanekhar A et al. Targeted deletion of fgl-2/fibroleukin in the donor modulates the immunologic response and acute vascular rejection in cardiac xenografts. Circulation 2005; 112: 248-256.
20. Cooper DKC. Xenoantigens and xenoantibodies. Xenotransplantation 1998; 5: 6-17.
21. Ezzelarab M, Ayares D, Cooper DKC. Carbohydrates in xenotransplantation. Immunol Cell Biol 2005; 83: 396-404.